WTW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Willis Towers Watson PLC (WTW) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. The stock's technical indicators are neutral to bearish, financial performance has shown significant declines, and there are no strong proprietary trading signals or recent positive catalysts to justify immediate entry. While analysts have mixed ratings with some positive outlooks, the overall sentiment and recent financial trends suggest a cautious approach.
The MACD is positive and expanding, indicating mild bullish momentum. However, RSI is neutral at 48.092, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest limited upside potential in the short term. The stock is trading near its pivot point of 289.227, with resistance at 295.656 and support at 282.798.
Completion of the FlowStone Partners acquisition, enhancing wealth management capabilities.
Launch of a new facility addressing U.S. casualty risks with specialized solutions.
Analysts like Barclays and Mizuho view AI as a productivity enabler and believe the selloff is overdone.
Significant YoY declines in revenue (-3.26%), net income (-41.01%), and EPS (-39.16%) in Q4
Bearish moving averages and lack of strong technical buy signals.
Stock trend analysis predicts a potential decline of -2.02% in the next week and -1.56% in the next month.
In Q4 2025, revenue dropped by -3.26% YoY to $2.936 billion, net income fell by -41.01% YoY to $735 million, and EPS declined by -39.16% YoY to $7.66. Gross margin remained flat YoY at 100%. These figures indicate a challenging financial environment for the company.
Analysts have mixed ratings. Barclays upgraded WTW to Equal Weight with a price target of $341, citing overdone selloff fears and AI's potential to enhance productivity. Mizuho and Piper Sandler maintain positive ratings but lowered price targets to $358 and $341, respectively. UBS and Truist have higher price targets of $409 and $400, reflecting optimism about organic growth. However, Morgan Stanley remains cautious, citing weak pricing and AI headwinds.
